|
|
Pulmonary Medicine
Research Funding
(listed alphabetically by Principal Investigator or by Section faculty member involved)
Academic Training in Pediatric Pulmonary Diseases: National Institutional Research Service Award+
Principal Investigator: Steven H. Abman, MD
Source: National Institutes of Health - HL07670-16
Amount: $1,800,000
Term: 2004-2009
Clinical Proteomics Center in Lung Disease
Principal Investigator: Frank J. Accurso, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - U01HL081335-01
Amount: $4,216,147
Term: 2005-2009
- Core A: Administrative
Principal Investigator: Frank J. Accurso, MD
Amount: $475,296
- Core B: Clinical
Principal Investigator: Steven H. Abman, MD
Co-Investigator: John P. Kinsella, MD
Co-Investigator: D. Dunbar Ivy, MD
Amount: $908,829
- Core C: Data Management
Principal Investigator: Gary O. Zerbe, PhD
Amount: $913,363
- Core D: Laboratory
Principal Investigator: Mark W. Duncan, PhD
Amount: $1,268,104
- Core E: Educational
Principal Investigator: Laurie A. Shroyer, PhD
Co-Investigator: Robin R. Deterding, MD
Amount: $650,555
Determinants of Early Pancreatic Injury in Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: National Institutes of Health - 1 R01 DK57755-027
Amount: $578,904
Term: 2001-2005
Cystic Fibrosis Center Grant
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - C017-05
Amount: $195,626
Term: 2005-2006
Cystic Fibrosis Center Grant
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - C017-04
Amount: $229,490
Term: 2004-2005
Cystic Fibrosis First-Year Clinical Fellowship for Jerimiah Lysinger, MD
Sponsor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - LYSING05B0
Amount: $42,000
Term: 2005-2006
Cystic Fibrosis First-Year Clinical Fellowship for Edith Towler-Zemanick, MD
Sponsor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - TOWLER04B0
Amount: $42,000
Term: 2004-2005
A Multicenter, Double-Blind, Placebo-Controlled, Phase II Study of Aerosolized tgAAVCF for the Treatment of Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Seattle Children's Hospital and Regional Medical Center (Cystic Fibrosis Foundation Therapeutics, Inc.)
Estimated Amount: $54,680
Term: 2004-2005
Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients with Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $35,151
Term: 2005-2006
The EPIC Observational Study: Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $21,477
Term: 2005-2010
Assessment of Induced Sputum as a Tool to Evaluate Anti-Inflammatory Agents in Patients with Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $72,520
Term: 2004-2006
A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial with Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients with Pulmonary Pseudomonas Aeruginosa Requiring Frequent Antibiotics (AIR CF2)
Principal Investigator: Frank J. Accurso, MD
Source: CORUS Pharmaceuticals, Inc.
Amount: $61,013
Term: 2005
A Phase 3, Open-label, Follow-Up Study of Multiple Courses of Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients (AIR CF3)
Principal Investigator: Frank J. Accurso, MD
Source: CORUS Pharmaceuticals, Inc.
Amount: $54,083
Term: 2005-2006
A Study of the Safety and Pharmacokinetics of 552-02 Following Fourteen Days of Dosing by Inhalation in Patients with Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Parion Sciences, Inc.
Amount: $29,822
Term: 2005
A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: PTC Therapeutics, Inc.
Amount: $67,253
Term: 2005-2006
Epidemiologic Study of Cystic Fibrosis: A Multicenter, Longitudinal Follow-Up Study of Patients with Cystic Fibrosis for Monitoring Pulmonary Function, Pulmonary Exacerbations and the Safety of Long-Term Treatment with Pulmozyme (Dornase Alfa)
Principal Investigator: Frank J. Accurso, MD
Source: Genentech, Inc.
Amount: $343,253
Term: 1994-present
The Role of Vascular Endothelial Growth Factor and Nitric Oxide in Lung Vascular Development+
Principal Investigator: Vivek Balasubramaniam, MD
Source: National Institutes of Health - 1 K08 HL073893-01
Amount: $653,400
Term: 2003-2008
INO Therapeutics Research Grant
Principal Investigator: Vivek Balasubramaniam, MD
Source: INO Therapeutics
Amount: $40,000
Term: 2004-2006
Colorado State Tobacco Education and Prevention Partnership
Principal Investigator: Keith L. Cavanaugh, MD
Source: State of Colorado
Amount: $96,228
Term: 2005-2006
Recommendations for the Evaluation, Diagnosis, and Treatment of the Child with Suspected Interstitial Lung Disease
Principal Investigator: Geoff Kurland, MD
Co-Principal Investigator: Robin R. Deterding, MD
Source: American Thoracic Society
Amount: $12,500
Term: 2005-2006
A Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Pediatric Patients with Cystic Fibrosis Lung Disease
Principal Investigator: Robin R. Deterding, MD
Source: Inspire Pharmaceuticals, Inc.
Amount: $39,365
Term: 2005
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Cystic Fibrosis Lung Disease
Principal Investigator: Robin R. Deterding, MD
Source: Inspire Pharmaceuticals, Inc.
Amount: $123,589
Term: 2005-2006
Serum Biomarkers and Risk Factors for Alzheimer's Disease
Principal Investigator: Mark W. Duncan, PhD
Source: Orentreich Foundation
Amount: $50,000
Term: 2005-2006
Practical Utility of Desorption Mass Spectroscopy Techniques
Principal Investigator: Mark W. Duncan, PhD
Source: Pfizer, Inc.
Amount: $199,091
Term: 2004-2005
Control of Bacterial Toxins by Viruses and Plasmids
Principal Investigator: Randall Holmes, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - R37 AI014107-3Q
Amount: $2,462,582
Term: 2005-2010
Viability Assay for Human Islet Transplantation
Principal Investigator: Mark Nicolls, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - R21 DK070203-02
Amount; $770,000
Term: 2004-2006
Cancer Center Core Grant++
Principal Investigator: Paul Bunn, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - P30 CA046934-17
Amount: $12,141,528
Term: 1988-2006
Mental Retardation and Development Disabilities Research Center++
Principal Investigator: Stephen I. Goodman, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - P30 HD004024-35
Amount: $3,709,360
Term: 2003-2008
Phospholipid Dynamics in Membrane Assembly++
Principal Investigator: Dennis Voelker, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - R37 GM032453-21
Amount: $2,500,000
Term: 2004-2008
Protein Expression Analysis in Cystic Fibrosis++
Principal Investigator: Mark W. Duncan, PhD
Source: Cystic Fibrosis Foundation
Amount: $871,604
Term: 2002-2005
Growth Factors and Signaling Pathways in Pulmonary Fibrosis++
Principal Investigator: Scott Worthen, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 HL073720-01
Amount: $2,561,838
Term: 2003-2007
Osmoregulated Proteins in the Inner Medulla++
Principal Investigator: Thomas Berl, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 DK66544-01
Amount: $250,000
Term: 2004-2009
Molecular Mechanism and Role of Corneal Adlehyde Dehydrogenase++
Principal Investigator: Vasilis Vasiliou, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 EY011490-06
Amount: $225,000
Term: 2004-2009
Practical Utility of Desorption Mass Spectroscopy Techniques++
Principal Investigator: Mark W. Duncan, PhD
Source: Pfizer, Inc.
Amount: $199,091
Term: 2004-2005
Modulation of Inflammation by Cholesterol and 3-Hydroxy-3 Coenzyme A Reductase Inhibitors: Role of the Lipid Raft++
Principal Investigator: Michael Fessler, MD
Co-Investigator: Mark W. Duncan, PhD
Source: American Heart Association
Amount: $197,000
Term: 2002-2007
Proteomics for Testing Hypotheses about Down Syndrome++
Principal Investigator: David Patterson, PhD
Principal Investigator: Mark W. Duncan, PhD (Consortium Subcontractor)
Source: National Institutes of Health - RO1 NS051539-01 A1
Amount: $770,000
Term: 2004-2008
Redefining the Major Peanut Allergens++
Principal Investigator: Stephen Dreskin, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health, National Institute of Allergy and Infectious Diseases - 5 R01 AI052164-03
Amount: $500,000
Term: 2003-2006
Myocardial Myotonic Dystophy Protein Kinase Function++
Principal Investigator: Benjamin Perryman, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - R01 HL064136-04
Amount: $445,950
Term: 2001-2005
Chemoprevention of Early Pulmonary Lesions in Mice by Anti-Inflammatory Drugs++
Principal Investigator: Al Malkinson, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health, National Cancer Institute - 5 R01 CA096133-02
Amount: $340,245
Term: 2002-2005
Development and Regeneration of the Endocrine Pancreas++
Principal Investigator: John Hutton, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases - 5 U19 DK061248-03
Amount: $988,732
Term: 2001-2004
Validation of Protein Biomarkers in Cystic Fibrosis
Principal Investigator: Steven W. Hunsucker, PhD
Source: Cystic Fibrosis Foundation - HUNSUC05A0
Amount: $258,034
Term: 2005-2008
Spirometry as an Outcome Measure in Preschool Children with Cystic Fibrosis
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Cystic Fibrosis Foundation
Amount: $920,504
Term: 2004-2007
Evaluation of Pulmonary Function Tests from Raised Lung Volumes as Outcome Measures for Clinical Trials in Infants with Cystic Fibrosis
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Seattle Children's Hospital and Regional Medical Center (Cystic Fibrosis Foundation)
Amount: $113,410
Term: 2003-2005
Neuro-Immune Interactions in Developing Airways**
Principal Investigator: Gary L. Larsen, MD
Source: National Institutes of Health - R01 HL67818
Amount: $225,000/yr
Term: 2002-2006
Childhood Asthma Research and Education (CARE) Network
Principal Investigator: Stanley J. Szefler, MD
Co-Investigators: Ronina A. Covar, MD, Gary L. Larsen, MD, and Marzena Krawiec, MD
Source: National Institutes of Health - HL64288
Amount: $4,732,241
Term: 2004-2006
Noninvasive Biomarkers of Proteolytic Activity in Cystic Fibrosis
Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health - K23 RR018611-01
Amount: $653,400
Term: 2003-2008
Genetic Disorders of Mucociliary Clearance
Principal Investigator: Michael R. Knowles, MD
Site Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health - ORD #1 U54 RR019480-01
Amount: $6,250,000
Amount (Site Funding): $390,776
Term: 2004-2009
Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis
Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health, General Clinical Research Center, and INO Therapeutics, Inc. - INOT50
Amount: $34,020
Term: 2004-2006
SCOR Grant: The Impact of Injury on the Immature Pulmonary Circulationº
Principal Investigator: Kurt R. Stenmark, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - P50 HL 57144
Amount: $6,415,929
Term: 2001-2006
- Project I: G-Proteins in Hypoxic Pulmonary Vascular Remodeling
Principal Investigator: Kurt R. Stenmark, MD
Amount: $2,076,662
- Project II: Inhaled NO and the Prevention of BPD
Principal Investigator: Steven H. Abman, MD
Co-Investigator: John P. Kinsella, MD
Amount: $1,860,606
- Project III: Prx Homeobox Genes in Pulmonary Vascular Homeostasis
Principal Investigator: Peter L. Jones, PhD
Amount: $1,456,087
- Clinical Core
Principal Investigator: John P. Kinsella, MD
Co-Investigator: Steven H. Abman, MD
Amount: $481,196
- Administrative Core
Principal Investigator: Kurt R. Stenmark, MD
Amount: $543,369
Assessment of Induced Sputum as a Tool to Evaluate Anti-Inflammatory Agents in Patients with Cystic Fibrosis
Principal Investigator: Jeffrey S. Wagener, MD
Source: Seattle Children's Hospital and Regional Medical Center
Amount (projected): $72,520
Term: 2004-2005
Bioavailability of Yasoo Formulation: A Pharmacokinetic Study
Principal Investigator: Jeffrey S. Wagener, MD
Source: Yasoo Health, Inc. - Yasoo-003
Amount (projected): $67,436
Term 2004-2005
A Phase 2, Randomized, Double-Blind, Parallel Dose-Ranging Study of Oral TheraCLEC-Total In Cystic Fibrosis Subjects with Exocrine Pancreatic Insufficiency (TC-2A)
Principal Investigator: Jeffrey S, Wagener, MD
Source: Altus Biologics, Inc.
Amount: $182,955
Term: 2004-2005
A Phase 1 Single-Dose, Dose-Escalation Trial Comparing Safety, Pharmacokinetics, and Delivery Time of Tobramycin Powder for Inhalation (TPI Powder) Administered by the Nektar T-326 Dry Powder Inhaler Device (T-326 Inhaler) to Tobramycin Solution for Inhalation (TOBI® at 300 mg/5 ml) Administered by a PARI LC PLUS™ Jet Nebulizer/DeVilbiss PulmoAide™ Compressor in Cystic Fibrosis (CF) Patients
Principal Investigator: Jeffrey S. Wagener, MD
Source: Chiron Pharmaceuticals, Inc.
Amount: $37,810
Term: 2003-2005
Treatment of Cystic Fibrosis Patients with Antioxidant Solution: A Pilot Study
Principal Investigator: Jeffrey S. Wagener, MD
Source: Yasoo Health, Inc.
Amount: $67,436
Term: 2004-2005
National Institutes of Health, National Heart Lung and Blood Institute, Collaborative Program in Bronchopulmonary Dysplasia**
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health, National Heart Lung and Blood Institute - 3 U01 HL 56263
Amount: $951,028
Term: 2003-2007
Mechanisms of Particulate-Induced Lung Injury (Project IV)**
Principal Investigator: Robert J. Mason, MD
Site Investigator: Carl W. White, MD
Source: Environmental Protection Agency - CR83084601
Amount: $83,840
Term: 2005-2006
Thioredoxin as a Mucolytic Agent in Cystic Fibrosis**
Principal Investigator: Carl W. White, MD
Source: Karasik Foundation
Amount: $35,000
Term: 2005-2006
Lung Epithelial Cell Survival Signaling in Ozone in Cystic Fibrosis and Normals**
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health - 1 R01 ES014448-01
Amount: $1,068,750
Term: 2005-2010
NOT-NS Medical Countermeasures to Chemical Terrorism**
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health - Supplemental ES012504
Amount: $78,000
Term: 2005-2006
2003-2004
Academic Training in Pediatric Pulmonary Diseases: National Institutional Research Service Award+
Principal Investigator: Steven H. Abman, MD
Source: National Institutes of Health - HL07670-16
Amount: $1,800,000
Term: 2004-2009
Academic Training in Pediatric Pulmonary Diseases: National Institutional Research Service Award+
Principal Investigator: Steven H. Abman, MD
Source: National Institutes of Health - HL07670-12
Amount: $1,605,925
Term: 1999-2004
Role of NO in the Regulation of Fetal Pulmonary Vasoreactivity and Growth*+
Principal Investigator: Steven H. Abman, MD
Source: March of Dimes Birth Defects Foundation - 6-FY00-124
Amount: $351,200
Term: 2000-2003
Inhaled Nitric Oxide in the Prevention of Chronic Lung Disease*+
Principal Investigator: John P. Kinsella, MD
Co-Investigators: Steven H. Abman, MD, and Adam A. Rosenberg, MD
Source: National Institutes of Health, National Heart, Lung and Blood
Institute - R01 HL64857-01A1
Amount: $7,080,990
Term: 2000-2004
Determinants of Early Pancreatic Injury in Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: National Institutes of Health - 1 R01 DK57755-027
Amount: $2,287,423
Term: 2001-2005
Effects of Pseudomonas aeruginosa on Inflammatory Gene Expression
Principal Investigator: David Rodman, MD
Co-Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - CFFPN0004-071
Amount: $1,500,000
Term: 2001-2004
Airway Clearance in Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - ACCURS98AO
Amount: $876,805
Term: 1999-2004
Cystic Fibrosis Therapeutic Development Center
Amount (Site Funding): Frank J. Accurso, MD
Co-Investigator: Jeffrey S. Wagener, MD
Source: Cystic Fibrosis Foundation - ACCURS98YO
Amount: $809,770
Term: 1998-2003
Project I-Airway Epithelial Cell Genomics and Pseudomonas aeruginosa Infection in Cystic Fibrosis
Principal Investigator: David Rodman, MD
Project I Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - CFFRODMAN00V0
Amount (Funding for Project 1): $375,000
Term: 2001-2004
Cystic Fibrosis Center Grant
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - C017-03
Amount: $221,254
Term: 2003-2004
A Multicenter, Double-Blind, Placebo-Controlled, Phase II Study of Aerosolized tgAAVCF for the Treatment of Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Seattle Children's Hospital and Regional Medical Center (Cystic Fibrosis Foundation Therapeutics, Inc.)
Estimated Amount: $54,680
Term: 2004-2005
Cystic Fibrosis First-Year Clinical Fellowship for Theresa Laguna, MD
Sponsor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - LAGUNA03B0
Amount: $42,000
Term: 2003-2004
Cystic Fibrosis First-Year Clinical Fellowship for Edith Towler-Zemanick, MD
Sponsor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - TOWLER04B0
Amount: $42,000
Term: 2004-2005
The Role of Vascular Endothelial Growth Factor and Nitric Oxide in Lung Vascular Development+
Principal Investigator: Vivek Balasubramaniam, MD
Source: National Institutes of Health - 1 K08 HL073893-01
Amount: $653,400
Term: 2003-2008
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of INS37217 Inhalation Solution in Subjects with Mild to Moderate Cystic Fibrosis Lung Disease
Principal Investigator: Robin R. Deterding, MD
Source: Cystic Fibrosis Foundation Therapeutics Network
Amount: $99,057
Term: 2002-2003
Responsive Virtual Human Technology Research National Science Foundation Grant
Principal Investigator: Robin R. Deterding, MD
Source: Research Triangle Institute - NSF 00-126
Amount: $42,704
Term: 2001-2004
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Cystic Fibrosis Lung Disease
Principal Investigator: Robin R. Deterding, MD
Sources: Inspire Pharmaceuticals, Inc.
Amount: $37,627
Term: 2004-2005
Cancer Center Core Grant++
Principal Investigator: Paul Bunn, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - P30 CA046934-17
Amount: $12,141,528
Term: 2001-2006
Mental Retardation and Development Disabilities Research Center++
Principal Investigator: Linda S. Crnic, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - P30 HD004024-35
Amount: $3,709,360
Term: 2003-2008
Phospholipid Dynamics in Membrane Assembly++
Principal Investigator: Dennis Voelker, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - R37 GM032453-21
Amount: $2,500,000
Term: 2004-2008
Protein Expression Analysis in Cystic Fibrosis++
Principal Investigator: Mark W. Duncan, PhD
Source: Cystic Fibrosis Foundation
Amount: $871,604
Term: 2002-2005
Redefining the Major Peanut Allergens++
Principal Investigator: Stephen Dreskins, MD, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 AI052164-2
Amount: $500,000
Term: 2003-2005
Growth Factors and Signaling Pathways in Pulmonary Fibrosis++
Principal Investigator: Scott Worthen, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 HL073720-01
Amount: $475,000
Term: 2003-2007
Osmoregulated Proteins in the Inner Medulla++
Principal Investigator: Thomas Berl, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 DK66544-01
Amount: $250,000
Term: 2004-2009
Molecular Mechanism and Role of Corneal Adlehyde Dehydrogenase++
Principal Investigator: Vasilis Vasiliou, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 EY011490-06
Amount: $225,000
Term: 2004-2009
Practical Utility of Desorption Mass Spectroscopy Techniques++
Principal Investigator: Mark W. Duncan, PhD
Source: Pfizer, Inc.
Amount: $199,091
Term: 2004-2005
Modulation of Inflammation by Cholesterol and 3-Hydroxy-3 Coenzyme A Reductase Inhibitors: Role of the Lipid Raft++
Principal Investigator: Michael Fessler, MD
Co-Investigator: Mark W. Duncan, PhD
Source: American Heart Association
Amount: $197,000
Term: 2002-2007
Proteomics for Testing Hypotheses about Down Syndrome++
Principal Investigator: David Patterson, PhD
Principal Investigator: Mark W. Duncan, PhD (Consortium Subcontractor)
Source: National Institutes of Health - RO1 NS051539-01 A1
Amount: $77,000
Term: 2004-2008
Spirometry as an Outcome Measure in Preschool Children with Cystic Fibrosis
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Cystic Fibrosis Foundation
Amount: $920,504
Term: 2004-2007
Evaluation of Pulmonary Function Tests from Raised Lung Volumes as Outcome Measures for Clinical Trials in Infants with Cystic Fibrosis
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Seattle Children's Hospital and Regional Medical Center (Cystic Fibrosis Foundation)
Amount: $113,410
Term: 2003-2005
The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Genentech, Inc.
Amount: $3,045
Term: 2001-2004
Neuro-Immune Interactions in Developing Airways**
Principal Investigator: Gary L. Larsen, MD
Source: National Institutes of Health - R01 HL67818
Amount: $225,000/yr
Term: 2002-2006
Childhood Asthma Research and Education (CARE) Network
Principal Investigator: Stanley J. Szefler, MD
Co-Investigators: Ronina A. Covar, MD, and Gary L. Larsen, MD
Source: National Institutes of Health - HL64288
Amount: $600,000/yr
Term: 1999-2004
Noninvasive Biomarkers of Proteolytic Activity in Cystic Fibrosis
Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health - K23 RR018611-01
Amount: $653,400
Term: 2003-2008
Genetic Disorders of Mucociliary Clearance
Principal Investigator: Michael R. Knowles, MD
Site Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health - ORD #1 U54 RR019480-01
Amount: $6,250,000
Amount (Site Funding): $390,776
Term: 2004-2009
Cystic Fibrosis Foundation Fourth-Year Clinical Fellowship Grant
Breath Condensate Collection in Children with Cystic Fibrosis
Principal Investigator: Scott D. Sagel, MD
Sponsor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - SAGEL02A0
Amount: $62,600
Term: 2002-2003
Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis
Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health, General Clinical Research Center, and INO Therapeutics, Inc. - INOT50
Amount: $34,020
Term: 2004-2006
SCOR Grant: The Impact of Injury on the Immature Pulmonary Circulationº
Principal Investigator: Kurt R. Stenmark, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - P50 HL 57144
Amount: $6,415,929
Term: 2001-2006
- Project I: G-Proteins in Hypoxic Pulmonary Vascular Remodeling
Principal Investigator: Kurt R. Stenmark, MD
Amount: $2,076,662
- Project II: Inhaled NO and the Prevention of BPD
Principal Investigator: Steven H. Abman, MD
Co-Investigator: John P. Kinsella, MD
Amount: $1,860,606
- Project III: Prx Homeobox Genes in Pulmonary Vascular Homeostasis
Principal Investigator: Peter L. Jones, PhD
Amount: $1,456,087
- Clinical Core
Principal Investigator: John P. Kinsella, MD
Co-Investigator: Steven H. Abman, MD
Amount: $481,196
- Administrative Core
Principal Investigator: Kurt R. Stenmark, MD
Amount: $543,369
Inhaled Tobramycin in Young Cystic Fibrosis Patients
Site Principal Investigator: Jeffrey S. Wagener, MD
Source: National Institutes of Health - 1R01 DK57755-03
Amount: $291,241
Term: 2000-2003
A Phase I, Open-Label Safety and Tolerability Study of Oral TheraCLEC
Site Principal Investigator: Jeffrey S. Wagener, MD
Source: Altus Biologics (TheraCLEC)
Amount: $206,610
Term: 2003-2004
Duration of Antimicrobial Treatment Effect Following Administration of Tobramycin for Inhalation (TOBI) in Young Children with Cystic Fibrosis
Site Principal Investigator: Jeffrey S. Wagener, MD
Source: Cystic Fibrosis Foundation Therapeutics Network
Amount: $95,890
Term: 2002-2003
Assessment of Induced Sputum as a Tool to Evaluate Anti-Inflammatory Agents in Patients with Cystic Fibrosis
Principal Investigator: Jeffrey S. Wagener, MD
Source: Seattle Children's Hospital and Regional Medical Center
Amount (projected): $72,520
Term: 2004-2005
Bioavailability of Yasoo Formulation: A Pharmacokinetic Study
Principal Investigator: Jeffrey S. Wagener, MD
Source: Yasoo Health, Inc. - Yasoo-003
Amount (projected): $67,436
Term 2004-2005
Single-Dose Escalation Study to Evaluate Safety of Nasal Administration of CFTR001 Gene Transfer Vector to Subjects with Cystic Fibrosis
Site Principal Investigator: Jeffrey S. Wagener, MD
Source: Copernicus Therapeutics
Amount: $55,849
Term: 2002-2003
Epidemiologic Study of Cystic Fibrosis: A Multicenter, Longitudinal Follow-Up Study of Patients with Cystic Fibrosis for Monitoring Pulmonary Function, Pulmonary Exacerbations, and the Safety of Long-Term Treatment with Pulmozyme (Dornase Alfa)
Principal Investigator: Jeffrey S. Wagener, MD
Source: Genentech, Inc.
Amount: $21,625
Term: 1997-present
Clinical Targets in Hyperoxic Mitochondrial Injury
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health - 2 U01 HL56263
Amount: $667,257
Term: 1999-2004
Role of Hexokinase in Lung Adaptation to Oxidant Stress
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health 2 R01 HL52732
Amount: $619,257/yr
Term: 1999-2004
2001-2002
Academic Training in Pediatric Pulmonary Diseases: National Institutional Research Service Award+
Principal Investigator: Steven H. Abman, MD
Source: National Institutes of Health - HL07670-12
Amount: $1,605,925
Term: 1999-2004
Development of Home Program for the Chronic Treatment of Severe Cardiopulmonary Diseases
Principal Investigator: Steven H. Abman, MD
Source: INO Therapeutics
Amount: $200,000
Term: 2001-2002
Home Care Program for Chronic NO Therapy+
Principal Investigator: Steven H. Abman, MD
Source: INO Therapeutics
Amount: $260,000
Term: 2000-2002
Role of Abnormal Lung Growth in the Development of Pulmonary Hypertension+
Principal Investigator: Steven H. Abman, MD
Source: American Heart Association National Grant-In-Aid - 9950265-N
Amount: $351,200
Term: 1999-2001
Role of NO in the Regulation of Fetal Pulmonary Vasoreactivity and Growth*+
Principal Investigator: Steven H. Abman, MD
Source: March of Dimes Birth Defects Foundation - 6-FY00-124
Amount: $351,200
Term: 2000-2003
Role of VEGF in Perinatal Pulmonary Hypertension*+
Principal Investigator: Steven H. Abman, MD
Source: National Institutes of Health - HL68702-01
Amount: $377,500
Term: 2001-2002
Airway Clearance in Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - ACCURS98AO
Amount: $876,805
Term: 1999-2004
Cystic Fibrosis Foundation Center Grant
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - C017
Amount: $200,958
Term: 2002-2003
Cystic Fibrosis Foundation Center Grant
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - C017
Amount: $179,751
Term: 2001-2002
Cystic Fibrosis Foundation Center Grant
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - C017
Amount: $173,550
Term: 2000-2001
Cystic Fibrosis Foundation Clinical Fellowships in Pediatric Pulmonology
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - Montgo02B0
Amount: $42,000
Term: 2002-2003
Cystic Fibrosis Foundation Clinical Fellowships in Pediatric Pulmonology
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - Sagel02A0
Amount: $62,600
Term: 2002-2003
Cystic Fibrosis Foundation Clinical Fellowships in Pediatric Pulmonology
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - Cavana01B0
Amount: $42,000
Term: 2001-2002
Cystic Fibrosis Foundation Clinical Fellowships in Pediatric Pulmonology
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - Cavana02B0
Amount: $45,000
Term: 2001-2002
Cystic Fibrosis Foundation Clinical Fellowships in Pediatric Pulmonology
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - Jones00B0
Amount: $36,000
Term: 2000-2001
Cystic Fibrosis Foundation Clinical Fellowships in Pediatric Pulmonology
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - WooldR00B0
Amount: $62,600
Term: 2001-2002
Cystic Fibrosis Therapeutic Development Center
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - ACCURS98YO
Amount: $809,770
Term: 1998-2003
Determinants of Early Pancreatic Injury in Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: National Institutes of Health - 1 R01 DK57755-027
Amount: $578,904
Term: 2001-2005
Effect of Postal Transport on Sputum Inflammatory Mediators in Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - ACCURS00A1
Amount: $34,420
Term: 2000-2002
A Prospective, Longitudinal Determination of Computed Tomography of the Chest and Systemic Markers of Inflammation in Children with Cystic Fibrosis Aged 6-10 Years with Pulmonary Abnormalities
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - ACCURS97A0
Amount: $306,025
Term: 1997-2001
Sputum Induction in Children with Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - ACCURS00A0
Amount: $126,942
Term: 2000-2002
Therapeutics Development Center Grant
Principal Investigator: Frank J. Accurso, MD
Co-Investigator: Jeffrey S. Wagener, MD
Source: Cystic Fibrosis Foundation Therapeutics, Inc. - ACCURS98YO
Amount: $809,770
Term: 1998-2003
A Phase 1b/2a Ascending Dose Cohort Study to Assess the Safety, Tolerability and Effects of Six Dose Levels of INS37217 and Placebo
Principal Investigator: Robin R. Deterding, MD
Source: Therapeutics Development Network (TDN) and Inspire Pharmaceuticals
Amount: $102,576
Term: 2001-2002
Responsive Virtual Human Technology Research National Science Foundation Grant
Principal Investigator: Robin R. Deterding, MD
Source: Research Triangle Institute - NSF 00-126
Amount: $42,704
Term: 2001-2004
Computer-Supported Collaborative Conferencing for Pediatric Problem-Based Learning
Principal Investigator: Carol Kamin, EdD
Co-Investigator: Robin R. Deterding, MD
Source: US Department of Education, Fund for the Improvement of Postsecondary Education (FIPSE) - P116B981537
Amount: $297,000
Term: 1998-2002
The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Genentech, Inc.
Amount: $3,045
Term: 2001-2004
Evaluation of Pulmonary Function from Raised Lung Volumes as Outcome Measures for Clinical Trials in Infants with Cystic Fibrosis
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Cystic Fibrosis Foundation Therapeutics Development Network
Amount: $13,836
Term: 2001-2002
Harry S. Shwachman Clinical Investigator Award - Infant Lung Function in Cystic Fibrosis
Principal Investigator: Gwendolyn S. Kerby, MD
Co-Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - Kerby98Q0
Amount: $120,000
Term: 1999-2001
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, 12-Week Study of Fluticasone Proprionate 44 mcg BID and 88 mcg BID Delivered via CFC MDI and a Valved Holding Chamber with Facemask in Subjects with Asthma Age 24-47 Months
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Glaxo Wellcome
Amount: $2,041
Term: 2000-2001
A Safety and Efficacy Study of Two Dosage-Levels of Pulmicort Respules vs. Placebo in Infants Between the Ages of 6-12 Months with Mild to Moderate Asthma
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Pediatric Pharmacology Research Unit and AstraZeneca
Amount: $5,590
Term: 2000-2002
A Safety, Tolerability and Efficacy Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects Birth to 48 m/o with Reactive Airways Disease in an Acute Setting
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Pediatric Pharmacology Research Unit and Sepracor
Term: 2001-2002
Inhaled Nitric Oxide in the Prevention of Chronic Lung Disease*+
Principal Investigator: John P. Kinsella, MD
Co-Investigators: Steven H. Abman, MD, and Adam A. Rosenberg, MD
Source: National Institutes of Health, National Heart, Lung and Blood
Institute - R01 HL64857-01A1
Amount: $7,080,990
Term: 2000-2004
Inflammation, Airways Reactivity and Asthma
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - HL36577
Amount: $956,029
Term: 2001-2002
- Mechanisms in Steroid-Resistant Asthma - Project 1
Project Leader: Donald Y. M. Leung, MD, PhD
Amount: $225,180/yr
- Role of T Lymphocytes in Airway Hyperresponsiveness - Project 2
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Gary L. Larsen, MD
Amount: $236,691/yr
- Eosinophil, Eicosanoid Biosynthesis and Metabolism - Project 4
Principal Investigator: Robert C. Murphy, PhD
Amount: $180,449/yr
- Morphology Core
Core Director: Gary L. Larsen, MD
Amount: $105,487/yr
- Administrative Core A
Principal Investigator: Erwin W. Gelfand, MD
Amount: $83,584/yr
- Clinical Core C
Principal Investigator: Richard J. Martin, MD
Amount: $124,639/yr
RSV Enhances Sensitization and Airway Responsiveness
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Gary L. Larsen, MD
Source: National Institutes of Health - R01 HL61005
Amount: $195,825/yr
Term: 1999-2003
Neuro-Immune Interactions in Developing Airways**
Principal Investigator: Gary L. Larsen, MD
Source: National Institutes of Health - R01 HL67818
Amount: $225,000/yr
Term: 2002-2006
Parent Education to Avoid Antibiotic Use in Acute Otitis Media
Principal Investigator: David P. McCormick, MD
Co-Investigators: Norman Friedman, MD, Tasnee Chonmaitree, MD, Kokab Saeed, MD, Constance Baldwin, PhD, and Tatsuo Uchida, MS
Source: Agency for Healthcare Research and Quality - R01 HS10613-01
Amount: $1,149,167
Term: 2000-2003
SCOR Grant: The Impact of Injury on the Immature Pulmonary Circulationº
Principal Investigator: Kurt R. Stenmark, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - P50 HL 57144
Amount: $6,415,929
Term: 2001-2006
- Project I: G-Proteins in Hypoxic Pulmonary Vascular Remodeling
Principal Investigator: Kurt R. Stenmark, MD
Amount: $2,076,662
- Project II: Inhaled NO and the Prevention of BPD
Principal Investigator: Steven H. Abman, MD
Co-Investigator: John P. Kinsella, MD
Amount: $1,860,606
- Project III: Prx Homeobox Genes in Pulmonary Vascular Homeostasis
Principal Investigator: Peter L. Jones, PhD
Amount: $1,456,087
- Clinical Core
Principal Investigator: John P. Kinsella, MD
Co-Investigator: Steven H. Abman, MD
Amount: $481,196
- Administrative Core
Principal Investigator: Kurt R. Stenmark, MD
Amount: $543,369
SCOR Grant: The Impact of Injury on the Immature Pulmonary Circulationº
Principal Investigator: Kurt R. Stenmark, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - P50 HL 57144
Amount: $7,145,567
Term: 1996-2001
- Project I: SMC Heterogeneity in the Pulmonary Vasculature
Principal Investigator: Kurt R. Stenmark, MD
Amount: $1,324,572
- Project II: Perlecan Heparan Sulfates: Molecular Mechanisms Underlying the Control of Vascular Smooth Muscle Cell Replication and Gene Expression During Normal Development and in Neonatal Pulmonary Hypertension
Principal Investigator: Kurt R. Stenmark, MD
Co-Investigator: Mary C. M. Weiser-Evans, PhD
Amount: $962,228
- Project III: NO-cGMP Cascade in Neonatal Pulmonary Hypertension
Principal Investigator: Steven H. Abman, MD
Co-Investigator: John P. Kinsella, MD
Co-Investigators Clinical Core: John P. Kinsella, MD, and Steven H. Abman, MD
Amount: $1,960,576
- Project IV: Oxidants, Energy and Pulmonary Vascular Development
Principal Investigator: Carl W. White, MD
Amount: $657,184
- Clinical Core
Principal Investigator: Adam A. Rosenberg, MD
Amount: $1,376,432
- Administrative Core
Principal Investigator: Kurt R. Stenmark, MD
Amount: $371,168
Childhood Asthma Research and Education (CARE) Network
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Gary L. Larsen, MD
Source: National Institutes of Health - 1 U10 HL64288
Amount: $567,053/yr
Term: 1999-2004
Effects of P. aeruginosa on Inflammatory Gene Expression
Principal Investigator: David Rodman, MD
Co-Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - CFFPN0004-071
Amount: $1,500,000
Term: 2001-2004
Project I-Airway Epithelial Cell Genomics and Pseudomonas aeruginosa Infection in CF
Principal Investigator: David Rodman, MD
Project I Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - CFFRODMAN00V0
Amount: Funding for Project 1: $375,000
Term: 2001-2004
Epidemiologic Study of Cystic Fibrosis
Principal Investigator: Jeffrey S. Wagener, MD
Source: Genentech, Inc.
Amount: $110,000
Term: 2000-2002
Evaluation of the Efficacy, Safety, Tolerance and Pharmacokinetics of Meropenem for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis
Principal Investigator: Jeffrey S. Wagener, MD
Source: AstraZeneca Pharmaceuticals
Amount: Clinical Trial: Funding dependent on enrollment
Term: 1998-2001
Inhaled Tobramycin in Young Cystic Fibrosis Patients
Principal Investigator: Jeffrey S. Wagener, MD
Source: National Institutes of Health - 1RO1 DK57755-027
Amount: $74,952
Term: 2001
Inhaled Tobramycin in Young Cystic Fibrosis Patients
Principal Investigator: Jeffrey S. Wagener, MD
Source: National Institutes of Health - 1R01 DK57755-03
Amount: $291,241
Term: 2000-2003
An Open-Label, Randomized Trial of Tobramycin Solution for Inhalation in Cystic Fibrosis Patients with Mild Lung Disease
Principal Investigator: Jeffrey S. Wagener, MD
Source: Cystic Fibrosis Foundation Therapeutics, Inc. - ACCURS99Y2
Amount: $10,000
Term: 2000-2002
A Phase I/II Study of Interferon Gamma-1b by Inhalation for the Treatment of Patients with Cystic Fibrosis
Principal Investigator: Jeffrey S. Wagener, MD
Source: InterMune Pharmaceuticals, Inc.
Amount: $80,000
Term: 2000-2002
Single-Dose Escalation Study to Evaluate Safety of Nasal Administration of CFTR001 Gene Transfer Vector to Subjects with Cystic Fibrosis
Principal Investigator: Jeffrey S. Wagener, MD
Source: Copernicus Therapeutics
Amount: $96,270
Term: 2002
Clinical Targets in Hyperoxic Mitochondrial Injury
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health - 2 U01 HL56263
Amount: $667,257
Term: 1999-2004
Mechanisms of Ozone Toxicity
Principal Investigator: Carl W. White, MD
Co-Principal Investigator: Robert C. Murphy, PhD
Source: Environmental Protection Agency
Amount: $90,000/yr
Term: 2001-2002
Role of Hexokinase in Lung Adaptation to Oxidant Stress
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health 2 R01 HL52732
Amount: $619,257/yr
Term: 1999-2004
1999-2000
SCOR Grant: The Developing Lung Circulation: Its Response to Injury -
NO-cGMP Cascade in the Perinatal Lungº
Principal Investigator: Steven H. Abman, MD
Source: National Institutes of Health, National Heart Lung and Blood Institute
Amount: $200,000/yr
Term: 1996-2001
Role of NO in Vasoregulation of the Perinatal Lung*+
Principal Investigator: Steven H. Abman, MD
Source: American Heart Association
Amount: $51,000/yr
Term: 1994-1999
Academic Training in Pediatric Pulmonary Diseases: National Institutional Research Service Award+
Principal Investigator: Steven H. Abman, MD
Co-Investigator: Gary L. Larsen, MD
Source: National Institutes of Health - HLBI T32
Amount: $220,000/yr
Term: 1999-2004
Role of Abnormal Lung Growth in the Development of Pulmonary Hypertension+
Principal Investigator: Steven H. Abman, MD
Source: American Heart Association National Grant-In-Aid
Amount: $150,000
Term: 1999-2001
Pediatric Heart Lung Center: Inhaled NO Therapy in Neonates and Infants with Heart and Lung Disease+
Principal Investigator: Steven H. Abman, MD
Source: Newborn Hope
Amount: $18,000
Term: 1999
Home Care Program for Chronic NO Therapy+
Principal Investigator: Steven H. Abman, MD
Source: INO Therapeutics
Amount: $150,000/yr
Term: 2000-2002
Unrestricted Educational Grant to the Pediatric Heart Lung Center+
Principal Investigator: Steven H. Abman, MD
Source: INO Therapeutics
Amount: $250,000
Term: 2000
Role of NO in the Regulation of Fetal Pulmonary Vasoreactivity and Growth*+
Principal Investigator: Steven H. Abman, MD
Source: March of Dimes Birth Defects Foundation
Amount: $96,800/yr
Term: 2000-2003
Cystic Fibrosis Foundation Center Grant
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $173,550
Term: 2000-2001
Cystic Fibrosis Foundation Center Grant
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $162,299
Term: 1999-2000
Cystic Fibrosis Therapeutic Development Center
Principal Investigator: Frank J. Accurso, MD
Co-Investigator: Jeffrey S. Wagener, MD
Source: Cystic Fibrosis Foundation
Amount: $809,770
Term: 1998-2003
Early Pathogenesis and Treatment of Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $400,000
Term: 1997-1999
A Prospective, Longitudinal Determination of Computed Tomography of the Chest and Systemic Markers of Inflammation in Children with Cystic Fibrosis Aged 6-10 Years with Pulmonary Abnormalities
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $306,025
Term: 1997-1999
A Randomized, Double-blinded, Placebo-controlled, Multi-Center Study of the Safety and Activity of TENOVIL (rHuIL-10) in Clinically Stable Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $65,112
Term: 2000-2001
A Phase II Multi-Center Randomized Trial of Tobramycin for Inhalation in Young Children with Cystic Fibrosis (TOBI Efficacy Study)
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $68,441
Term: 2000-2002
Sputum Induction in Children with Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $126,942
Term: 2000-2002
Cystic Fibrosis Foundation Clinical Fellowship
Principal Investigators: Monica Jones, MD, and Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $36,000
Term: 1999-2000
Harry Shwachman Cystic Fibrosis Clinical Investigator Award: Infant Lung Function in Cystic Fibrosis
Principal Investigator: Gwendolyn Kerby, MD
Source: Cystic Fibrosis Foundation
Amount: $75,000/yr
Term: 1998-2001
Inhaled Nitric Oxide in the Prevention of Chronic Lung Disease*+
Principal Investigator: John P. Kinsella, MD
Co-Investigator: Steven H. Abman, MD
Source: National Institutes of Health
Amount: $7,080,990
Term: 2000-2004
Abnormal Lung Development in a Genetic Model of Pulmonary Hypertension
Principal Investigator: Timothy Le Cras, PhD
Source: American Heart Association
Amount: $65,000/yr
Term: 1999-2002
Cystic Fibrosis Foundation Clinical Fellowship
Principal Investigators: Jamie Wooldridge, MD, and Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $55,000
Term: 2000-2001
Cystic Fibrosis Foundation Clinical Fellowship
Principal Investigators: Scott Sagel, MD, and Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $36,000
Term: 1999-2000
Cystic Fibrosis Foundation Clinical Fellowship
Principal Investigators: Jamie Woolridge, MD, and Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $40,000
Term: 1999-2000
Phase IIA Multiple Dose Escalation Study to Evaluate Lung-Specific Bioefficacy of Oral Administration with DMP777 in Adult Patients 18 Years of Age and Older with Cystic Fibrosis
Principal Investigator: Jeffrey S. Wagener, MD
Source: Dupont Merck Pharmaceutical
Amount: $90,000
Term: 1998-1999
Note: Additional Research Funding for Pulmonary Medicine faculty is listed under Children's Outcomes Research Program, National Jewish Medical and Research Center and Pediatric Medical Education.
|
|
